Resting and exercise physiology in interstitial lung diseases

Clinics in Chest Medicine

Volumn 25, Issue 3, 2004, Pages 435-453

  Lama, Vibha N ^a   Martinez, Fernando J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIRWAY OBSTRUCTION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EXPIRATORY FLOW RATE; EXPIRATORY RESERVE VOLUME; HUMAN; INSPIRATORY CAPACITY; INSPIRATORY RESERVE VOLUME; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUNG HEMOSIDEROSIS; LUNG VOLUME; MEDICAL DOCUMENTATION; MEMBRANE STEADY POTENTIAL; MUSCLE EXERCISE; MUSCLE FUNCTION; OXYGEN SATURATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SARCOIDOSIS; SYSTEMIC SCLEROSIS;

DIAGNOSIS, DIFFERENTIAL; EXERCISE TEST; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG VOLUME MEASUREMENTS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RESPIRATORY MECHANICS; SARCOIDOSIS, PULMONARY; SCLERODERMA, DIFFUSE;

EID: 4344570739     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2004.05.005     Document Type: Review

References (218)

1. Schwarz M. Approach to the understanding, diagnosis, and management of interstitial lung disease. Schwarz M., King T. Jr. Interstitial lung disease. 1998;3-30 B.C. Dekker, Hamilton, Ontario
2. O'Donnell D. Physiology of interstitial lung disease. Schwarz M., King T. Jr. Interstitial lung disease. 1998;51-70 B.C. Dekker, Hamilton, Ontario
3. Schlueter D.P., Fink J.N., Sosman A.J. Pulmonary function in pigeon breeders' disease: a hypersensitivity pneumonitis. Ann Intern Med. 70(3):1969;457-470
4. Glaister D.H., Schroter R.C., Sudlow M.F., Milic-Emili J. Bulk elastic properties of excised lungs and the effect of a transpulmonary pressure gradient. Respir Physiol. 17(3):1973;347-364
5. Macklem P., Becklake M. The relationship between mechanical and diffusing properties of the lung in health and disease. Am Rev Respir Dis. 87:1963;47-56
6. Fulmer J., Roberts W., Von Gal E., Crystal R. Morphologic-physiologic correlates of the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis. J Clin Invest. 63:1979;665-676
7. Javaheri S., Sicilian L. Lung function, breathing pattern, and gas exchange in interstitial lung disease. Thorax. 47(2):1992;93-97
8. Yernault J.C., de Jonghe M., de Coster A., Englert M. Pulmonary mechanics in diffuse fibrosing alveolitis. Bull Physiopathol Respir. 11(2):1975;231-244
9. Bjerke R., Tashkin D., Clements P., Chopra S., Gong H. Jr., Bein M. Small airways in progressive systemic sclerosis (PSS). Am J Med. 66:1979;201-209
10. Jezek V., Fucik J., Michaljanic A., Jeskova L. The prognostic significance of functional tests in kryptogenic fibrosing alveolitis. Bull Eur Physiolpathol Respir. 16:1980;711-720
11. Carrington C., Gaensler E., Coutu R., FitzGerald M., Gupta R. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med. 298(15):1978;801-809
12. Tukiainen P., Taskinen E., Holsti P., Korhola O., Valle M. Prognosis of cryptogenic fibrosing alveolitis. Thorax. 38:1983;349-355
13. Gottlieb D., Snider G., Phan S., et al. Lung function in pulmonary fibrosis. 1995;Marcel Dekker, New York
14. Scano G., Monechi G., Stendardi L., LoConte C., Van Meerhaeghe A., Sergysels R. Functional evaluation in stage I pulmonary sarcoidosis. Respiration (Herrlisheim). 49:1986;195-203
15. Renzi G., Dutton R. Pulmonary function in diffuse sarcoidosis. Respiration (Herrlisheim). 31:1974;124-136
16. Dutton R., Renzi P., Lopez-Majano V., Renzi G. Airway function in sarcoidosis: smokers vs nonsmokers. Respiration (Herrlisheim). 43:1982;164-173
17. Stjernberg N., Thunell M. Pulmonary function in patients with endobronchial sarcoidosis. Acta Med Scand. 215(2):1984;121-126
18. Bradvik I., Wollmer P., Simonsson B., Albrechtsson U., Lyttkens K., Jonson B. Lung mechanics and their relationship to lung volumes in pulmonary sarcoidosis. Eur Respir J. 2:1989;643-651
19. Argyropoulou P., Patakas D., Louridas G. Airway function in stage I and stage II pulmonary sarcoidosis. Respiration (Herrlisheim). 46:1984;17-25
20. Radwan L., Grebska E., Koziorowski A. Small airways function in pulmonary sarcoidosis. Scand J Respir Dis. 59:1978;37-43
21. Levinson R.S., Metzger L.F., Stanley N.N., Kelsen S.G., Altose M.D., Cherniack N.S., et al. Airway function in sarcoidosis. Am J Med. 62(1):1977;51-59
22. Sharma O., Johnson R. Airway obstruction in sarcoidosis. A study of 123 nonsmoking black American patients with sarcoidosis. Chest. 94(2):1988;343-346
23. McCarthy D., Sigurdson M. Lung function in pulmonary sarcoidosis. Ir J Med Sci. 147:1978;413-419
24. Miller A., Teirstein A.S., Jackler I., Chuang M., Siltzbach L.E. Airway function in chronic pulmonary sarcoidosis with fibrosis. Am Rev Respir Dis. 109(2):1974;179-189
25. Harrison B.D., Shaylor J.M., Stokes T.C., Wilkes A.R. Airflow limitation in sarcoidosis-a study of pulmonary function in 107 patients with newly diagnosed disease. Respir Med. 85(1):1991;59-64
26. Lavergne F., Clericki C., Sadoun D., Brauner M.W., Battesti J., Valeyre D. Airway obstruction in bronchial sarcoidosis. Outcome with treatment. Chest. 116:1999;1194-1199
27. Cieslicki J., Zych D., Zielinski J. Airways obstruction in patients with sarcoidosis. Sarcoidosis. 8:1991;42-44
28. Perez T., Remy-Jardin M., Cortet B. Airways involvement in rheumatoid arthritis. Clinical, functional, and HRCT findings. Am J Respir Crit Care Med. 157:1998;1658-1665
29. Radoux V., Menard H.A., Begin R., Decary F., Koopman W.J. Airways disease in rheumatoid arthritis patients. One element of a general exocrine dysfunction. Arthritis Rheum. 30(3):1987;249-256
30. Vergnenegre A., Pugnere N., Antonini M.T., Arnaud M., Melloni B., Treves R., et al. Airway obstruction and rheumatoid arthritis. Eur Respir J. 10(5):1997;1072-1078
31. Cherniack R., Colby T., Flint A., Thurlbeck W., Waldron J. Jr., Ackerson L., et al. Correlation of structure and function in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 151(4):1995;1180-1188
32. Doherty M., Pearson M., O'Grady E., Pellegrini V., Calverley P. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax. 52:1997;998-1002
33. Dunn T., Watters L., Hendrix C., Cherniack R., Schwarz M., King T. Gas exchange at a given degree of volume restriction is different in sarcoidosis and idiopathic pulmonary fibrosis. Am J Med. 85:1988;221-224
34. Keogh B., Lakatos E., Price D., Crystal R. Importance of the lower respiratory tract in oxygen transfer. Exercise testing in patients with interstitial and destructive lung diseases. Am Rev Respir Dis. 129(Suppl):1984;S76-S80
35. DiMarco A., Kelsen S., Cherniack N., Gothe B. Occlusion pressure and breathing pattern in patients with interstitial lung disease. Am Rev Respir Dis. 127:1983;425-430
36. Renzi G., Milic-Emili J., Grassino A. The pattern of breathing in diffuse lung fibrosis. Bull Eur Physiolpathol Respir. 18(3):1982;461-472
37. Brack T., Jubran A., Tobin M.J. Dyspnea and decreased variability of breathing in patients with restrictive lung disease. Am J Respir Crit Care Med. 165(9):2002;1260-1264
38. Marciniuk D.D., Gallagher C.G. Clinical exercise testing in interstitial lung disease. Clin Chest Med. 15(2):1994;287-303
39. Bye P.T., Anderson S.D., Woolcock A.J., Young I.H., Alison J.A. Bicycle endurance performance of patients with interstitial lung disease breathing air and oxygen. Am Rev Respir Dis. 126(6):1982;1005-1012
40. Burdon J.G., Killian K.J., Jones N.L. Pattern of breathing during exercise in patients with interstitial lung disease. Thorax. 38(10):1983;778-784
41. Marciniuk D.D., Sridhar G., Clemens R.E., Zintel T.A., Gallagher C.G. Lung volumes and expiratory flow limitation during exercise in interstitial lung disease. J Appl Physiol. 77(2):1994;963-973
42. Marciniuk D.D., Watts R.E., Gallagher C.G. Dead space loading and exercise limitation in patients with interstitial lung disease. Chest. 105(1):1994;183-189
43. Anderson S.D., Bye P.T. Exercise testing in the evaluation of diffuse interstitial lung disease. Aust N Z Med J. 14(5 Suppl 3):1984;762-768
44. Markovitz G.H., Cooper C.B. Exercise and interstitial lung disease. Curr Opin Pulm Med. 4(5):1998;272-280
45. Hansen J., Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest. 109:1996;1566-1576
46. Sue D.Y., Oren A., Hansen J.E., Wasserman K. Diffusing capacity for carbon monoxide as a predictor of gas exchange during exercise. N Engl J Med. 316(21):1987;1301-1306
47. Hamilton A.L., Killian K.J., Summers E., Jones N.L. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med. 152(6 Pt 1):1995;2021-2031
48. Jones N.L., Killian K.J. Exercise limitation in health and disease. N Engl J Med. 343(9):2000;632-641
49. Weisman I.M. Cardiopulmonary exercise testing in the preoperative assessment for lung resection surgery. Semin Thorac Cardiovasc Surg. 13:2001;116-125
50. Wagner P.D. Determinants of maximal oxygen transport and utilization. Annu Rev Physiol. 58:1996;21-50
51. Dempsey J.A., Babcock M.A. An integrative view of limitations to muscular performance. Adv Exp Med Biol. 384:1995;393-399
52. Jones N. Determinants of breathing pattern in exercise. Whipp B.J., Wasserman K. Exercise. Pulmonary physiology and pathophysiology. 1991;99-119 Marcel Dekker, New York
53. Jones N.L., Rebuck A.S. Tidal volume during exercise in patients with diffuse fibrosing alveolitis. Bull Eur Physiopathol Respir. 15(2):1979;321-328
54. Gowda K., Zintel T., McParland C., Orchard R., Gallagher C.G. Diagnostic value of maximal exercise tidal volume. Chest. 98(6):1990;1351-1354
55. Renzi G., Milic-Emili J., Grassino A.E. The pattern of breathing in diffuse lung fibrosis. Bull Eur Physiopathol Respir. 18(3):1982;461-472
56. Spiro S.G., Dowdeswell I.R., Clark T.J. An analysis of submaximal exercise responses in patients with sarcoidosis and fibrosing alveolitis. Br J Dis Chest. 75(2):1981;169-180
57. Agusti A.G., Roca J., Gea J., Wagner P.D., Xaubet A., Rodriguez-Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 143(2):1991;219-225
58. Denison D., Al-Hillawi H., Turton C. Lung function in interstitial lung disease. Seminars in Respiratory Medicine. 6:1984;40-54
59. Risk C., Epler G., Gaensler E. Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest. 85(1):1984;69-74
60. Jernudd-Wilhelmsson Y., Hornblad Y., Hedenstierna G. Ventilation- perfusion relationships in interstitial lung disease. Eur J Respir Dis. 68(1):1986;39-49
61. Wagner P.D. Ventilation-perfusion matching during exercise. Chest. 101(5 Suppl):1992;192S-198S
62. Hawrylkiewicz I., Izdebska-Makosa Z., Grebska E., Zielinski J. Pulmonary haemodynamics at rest and on exercise in patients with idiopathic pulmonary fibrosis. Bull Eur Physiopathol Respir. 18(3):1982;403-410
63. Weitzenblum E., Ehrhart M., Rasaholinjanahary J., Hirth C. Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration (Herrlisheim). 44(2):1983;118-127
64. Bush A., Busst C.M. Cardiovascular function at rest and on exercise in patients with cryptogenic fibrosing alveolitis. Thorax. 43(4):1988;276-283
65. Enson Y., Thomas H.M. III, Bosken C.H., Wood J.A., Leroy E.C., Blanc W.A., et al. Pulmonary hypertension in interstitial lung disease: relation of vascular resistance to abnormal lung structure. Trans Assoc Am Physicians. 88:1975;248-255
66. Wasserman K. Principles of exercise testing and interpretation: including pathophysiology and clinical applications. 3rd edition:1999;Lippincott Williams & Wilkins, Philadelphia
67. Baughman R.P., Gerson M., Bosken C.H. Right and left ventricular function at rest and with exercise in patients with sarcoidosis. Chest. 85(3):1984;301-306
68. Davidson D., Stalcup S.A., Mellins R.B. Systemic hemodynamics affecting cardiac output during hypocapnic and hypercapnic hypoxia. J Appl Physiol. 60(4):1986;1230-1236
69. Widimsky J., Riedel M., Stanek V. Central haemodynamics during exercise in patients with restrictive pulmonary disease. Bull Eur Physiopathol Respir. 13(3):1977;369-379
70. Gibbons W.J., Levy R.D., Nava S., Malcolm I., Marin J.M., Tardif C., et al. Subclinical cardiac dysfunction in sarcoidosis. Chest. 100(1):1991;44-50
71. Epler G., McCloud T., Gaensler E., Rosner B. Normal chest roentgenograms in chronic diffuse interstitial lung disease. N Engl J Med. 298:1979;934-939
72. Orens J., Kazerooni E., Martinez F., Curtis J., Gross B., Flint A., et al. The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy. A prospective study. Chest. 108:1995;109-115
73. Crystal R., Fulmer J., Roberts W., Moss M., Line B., Reynolds H. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med. 85:1976;769-788
74. Hadeli K., Siegel E., Sherrill D., Beck K., Enright P. Predictors of oxygen desaturation during submaximal exercise in 8,000 patients. Chest. 120(1):2001;88-92
75. Jensen L., Onyskiw J., Prasad N. Meta-analysis of arterial oxygen saturation monitoring by pulse oximetry in adults. Heart Lung. 27(6):1998;387-408
76. Chetta A., Aiello M., Foresi A., Marangio E., D'Ippolito R., Castagnaro A., et al. Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 18:2001;170-175
77. Lama V., Flaherty K., Toews G., Colby T., Travis W., Long Q., et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 168(9):2003;1084-1090
78. Chang J., Curtis J., Patrick D., Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest. 116:1999;1175-1182
79. Mihailovic-Vucinic V., Zugic V., Videnovic-Ivanov J. New observations on pulmonary function changes in sarcoidosis. Curr Opin Pulm Med. 9(5):2003;436-441
80. Judson M., Thompson B., Rabin D., Steimel J., Knattereud G., Lackland D., et al and ACCESS Research Group. The diagnostic pathway to sarcoidosis. Chest 2003;123(2):406-12
81. Augusti A., Roca J., Rodriguez-Roisin R., Xaubet A., Agusti-Vidal A. Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir J. 1:1988;510-516
82. Williams R., Hugh-Jones P. The significance of lung function changes in asbestosis. Thorax. 15:1960;109-119
83. Bohadana A., Peslin R., Poncelet B., Hannhart B. Lung mechanical properties in silicosis and silicoanthracosis. Bull Eur Physiopathol Respir. 16:1980;521-532
84. Wells A., Hansell D., Rubens M., King A., Cramer D., Black C., et al. Fibrosing alveolitis in systemic sclerosis. Indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum. 40:1997;1229-1236
85. Bjoraker J., Ryu J., Edwin M., Myers J., Tazelaar H., Schoreder D., et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 157:1998;199-203
86. Sudduth C.D., Strange C., Cook W.R., Miller K.S., Baumann M., Collop N.A., et al. Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. Am J Med. 95(4):1993;413-418
87. Sietsema K., Kraft M., Ginzton L., Sharma O. Abnormal oxygen uptake responses to exercise in patients with mild pulmonary sarcoidosis. Chest. 102:1992;838-845
88. Myers J. NSIP, UIP, and the ABCs of idiopathic interstitial pneumonias. Eur Respir J. 12:1998;1003-1004
89. Fulmer J., Roberts W., Crystal R. Diffuse fibrotic lung disease: a correlative study. Chest. 69(Suppl):1976;263-265
90. Keogh B., Crystal R. Pulmonary function testing in interstitial pulmonary disease. What does it tell us? Chest. 78:1980;856-865
91. Kanengiser L., Rapoport D., Epstein H., Goldring R. Volume adjustment of mechanics and diffusion in interstitial lung disease. Lack of clinical significance. Chest. 96:1989;1036-1042
92. Watters L., King T., Schwarz M., Waldron J., Stanford R., Cherniack R. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis. 133:1986;97-103
93. Gaensler E., Carrington C., Coutu R., Fitzgerald M. Radiographic- physiologic-pathologic correlations in interstitial pneumonias. Prog Respir Res. 8:1975;223-241
94. Chinet T., Jaubert F., Dusser D., Danel C., Chretien J., Huchon G. Effects of inflammation and fibrosis on pulmonary function in diffuse lung fibrosis. Thorax. 45(9):1990;675-678
95. Nordenfelt I., Svensson G. The transfer factor (diffusing capacity) as a predictor of hypoxaemia during exercise in restrictive and chronic obstructive pulmonary disease. Clin Physiol. 7(5):1987;423-430
96. Bradvick I., Wollmer P., Blom-Bulow B., Albrechtsson U., Johnson B. Lung mechanics and gas exchange in steroid treated pulmonary sarcoidosis. A seven year follow-up. Sarcoidosis. 8:1991;105-114
97. Wells A., King A., Rubens M., Cramer D., duBois R., Hansell D. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med. 155:1997;1367-1375
98. Xaubet A., Agusti C., Luburich P., Roca J., Monton C., Ayuso M., et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 158:1998;431-436
99. Wells A.U., Hansell D.M., Rubens M.B., Cailes J.B., Black C.M., du Bois R.M. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. Am J Respir Crit Care Med. 155(5):1997;1657-1664
100. Brantly M., Avila N., Shotelersuk V., Lucero C., Huizing M., Gahl W. Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansk-Pudlak syndrome, due to mutations in HPS-1. Chest. 117:2000;129-136
101. King T. Jr., Schwarz M., Brown K., Tooze J., Colby T., Waldron J. Jr., et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 164:2001;1025-1032
102. Wells A., Desai S., Rubens M., Goh N., Cramer D., Nicholson A., et al. Idiopathic pulmonary fibrosis. A composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 167:2003;962-969
103. Rudd R., Haslam P., Turner-Warwick M. Cryptogenic fibrosing alveolitis: relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis. 124:1981;1-8
104. Wells A. Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis. Thorax. 53:1998;1080-1087
105. Gay S., Kazerooni E., Toews G., Lynch J. III, Gross B., Cascade P., et al. Idiopathic pulmonary fibrosis. Predicting response to therapy and survival. Am J Respir Crit Care Med. 157:1998;1063-1072
106. Turner-Warwick M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax. 35:1980;171-180
107. Hanson D., Winterbauer R., Kirtland S., Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest. 108:1995;305-310
108. Hubbard R., Johnston I., Britton J. Survival in patients with cryptogenic fibrosing alveolitis. A population-based cohort study. Chest. 113:1998;396-400
109. Douglas W., Ryu J., Schroeder D. Idiopathic pulmonary fibrosis. Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med. 161:2000;1172-1178
110. Erbes R., Schaberg T., Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest. 111:1997;51-57
111. Raghu G., Johnson W., Lockhart D., Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, Pirfenidone. Results of a prospective, open-label phase II study. Am J Respir Crit Care Med. 159:1999;1061-1069
112. Mogulkoc N., Brutsche M., Bishop P., Greaves S., Horrocks A., Egan J. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med. 164(1):2001;103-108
113. Latsi P.I., du Bois R.M., Nicholson A.G., Colby T.V., Bisirtzoglou D., Nikolakopoulou A., et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 168(5):2003;531-537
114. Johnson M., Kwan S., Snell N., Nunn A., Darbyshire J., Turner-Warwick M. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax. 44:1989;280-288
115. Schwartz D., Helmers R., Galvin J., Van Fossen D.S., Frees K.L., Dayton C.S., et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 149:1994;450-454
116. American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias Am J Respir Crit Care Med. 165:2002;277-304
117. Nicholson A.G., Fulford L.G., Colby T.V., Du Bois R.M., Hansell D.M., Wells A.U. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 166(2):2002;173-177
118. King T. Jr., Tooze J., Schwarz M., Brown K., Cherniack R. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 164:2001;1171-1181
119. Miki K., Maekura R., Hiraga T., Okuda Y., Okamato T., Hirotani A., et al. Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. Respir Med. 97:2003;482-490
120. Mapel D., Samet J., Coultas D. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest. 110:1996;1058-1067
121. Harrison N., Myers A., Corrin B., Soosay G., Dewar A., Black C., et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis. 144:1991;706-713
122. Diot E., Boissinot E., Asquier E., Guilmot J., Lemarie E., Valat C., et al. Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. Chest. 114:1998;1623-1629
123. Pignone A., Matucci-Cerinic M., Lombardi A., Fedi R., Fargnoli R., De Dominicis R., et al. High resolution computed tomography in systemic sclerosis. Real diagnostic utilities in the assessment of pulmonary involvement and comparison with other modalities of lung investigation. Clin Rheumatol. 11(4):1992;465-472
124. Domagala-Kulawik J., Hoser G., Doboszynska A., Kawiak J., Droszcz W. Interstitial lung disease in systemic sclerosis: comparison of BALF lymphocyte phenotype and DLCO impairment. Respir Med. 92:1998;1295-1301
125. King T.E. Connective tissue disease. Schwarz M.I., King T.E. Interstitial lung disease. 1998;451-505 B.C. Dekker, Hamilton (Ontario, Canada)
126. Steen V., Medsger T. Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 43:2000;2437-2444
127. Scussel-Lonzetti L., Joyal F., Raynaud J., Roussin A., Rich E., Goulet J., et al. Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore). 81:2002;154-167
128. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis. Demographic, clinical and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 81:2002;139-153
129. MacGregor A., Canavan R., Knight C., Denton C., Davar J., Coghlan J., et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatol. 40:2001;453-459
130. Medsger T., Masai A., Rodnan G., Benedek T.G., Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med. 75:1971;369-376
131. Bennett R., Bluestone R., Holt P., Bywaters E. Survival in scleroderma. Ann Rheum Dis. 30:1971;581-588
132. Eason R., Tan P., Gow P. Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features. Aust N Z J Med. 11:1981;657-662
133. Peters-Golden M., Wise R.A., Hochberg M.C., Stevens M.B., Wigley F.M. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med. 77(6):1984;1027-1034
134. Wells A., Cullinan P., Hansell D., Rubens M., Black C., Newman-Taylor A., et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 149:1994;1583-1590
135. Giersson A., Wollheim F., Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis. 60:2001;1117-1122
136. Morgan C., Knight C., Lunt M., Black C., Silman A. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis. 62:2003;146-150
137. Steen V.D., Conte C., Owens G.R., Medsger T.A. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 37(9):1994;1283-1289
138. Jacobsen S., Ullman S., Shen G., Wiik A., Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol. 28(11):2001;2454-2459
139. Bryan C., Knight C., Black C., Silman A. Prediction of five-year survival following presentation with scleroderma. Development of a simple model using three disease factors at first visit. Arthritis Rheum. 42(12):1999;2660-2665
140. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 62:2003;97-99
141. Steen V., Graham G., Conte C., Owens G., Medsger T. Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum. 35(7):1992;765-770
142. Stupi A.M., Steen V.D., Owens G.R., Barnes E.L., Rodnan G.P., Medsger T.A. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 29(4):1986;515-524
143. Ungerer R.G., Tashkin D.P., Furst D., Clements P.J., Gong H., Bein M., et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med. 75(1):1983;65-74
144. Mukerjee D., St. George D., Knight C., Davar J., Wells A., du Bois R., et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatol. 43:2004;461-466
145. Medsger T. Jr., Silman A., Steen V., Black C., Akesson A., Bacon P., et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 26:1999;2159-2167
146. Winterbauer R.H., Hutchinson J.F. Use of pulmonary function tests in the management of sarcoidosis. Chest. 78(4):1980;640-647
147. Young R.C., Carr C., Shelton T.G., Mann M., Ferrin A., Laurey J.R., et al. Sarcoidosis: relationship between changes in lung structure and function. Am Rev Respir Dis. 95(2):1967;224-238
148. Carrington C., Gaensler E., Mikus J., Schachter W., Burke G., Goff A. Structure and function in sarcoidosis. Ann N Y Acad Sci. 278:1976;265-283
149. Young R., Loudon R., Krumholz R., Harkleroad L., Branam G., Weg J. Pulmonary sarcoidosis: I. Pathologic considerations. Am Rev Respir Dis. 97:1968;997-1008
150. Huang C.T., Heurich A.E., Rosen Y., Moon S., Lyons H.A. Pulmonary sarcoidosis: roentgenographic, functional, and pathologic correlations. Respiration (Herrlisheim). 37(6):1979;337-345
151. McLoud T., Epler G., Gaensler E., Burke G., Carrington C. A radiographic classification of sarcoidosis. Physiologic correlation. Invest Radiol. 17:1982;129-138
152. Lin Y., Haslam P., Turner-Warwick M. Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests. Thorax. 40:1985;501-507
153. Muller N., Mawson J., Mathieson J., Abboud R., Ostrow D., Champion P. Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology. 171:1989;613-618
154. Remy-Jardin M., Giraud F., Remy J., Wattinne L., Wallaert B., Duhamel A. Pulmonary sarcoidosis: role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment. Radiology. 191(3):1994;675-680
155. Bergin C., Bell D., Coblentz C., Chiles C., Gamsu G., MacIntyre N., et al. Sarcoidosis: correlation of pulmonary parenchymal pattern at CT with results of pulmonary function tests. Radiology. 171:1989;619-624
156. Hansell D., Milne D., Wilsher M., Wells A. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology. 209:1998;697-704
157. Muers M., Middleton W., Gibson G., Prescott R., Mitchell D., Connolly C., et al. A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society Study of Long-Term Corticosteroid Treatment. Sarcoidosis Vasc Diffuse Lung Dis. 14:1997;46-56
158. Abehsera M., Valeyre D., Grenier P., Jaillet H., Battesti J.P., Brauner M.W. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol. 174(6):2000;1751-1757
159. Medinger A., Khouri S., Rohatgi P. Sarcoidosis. The value of exercise testing. Chest. 120:2001;93-101
160. Delobbe A., Perrault H., Maitre J., Bobin S., Hossein-Foucher C., Wallaert B., et al. Impaired exercise response in sarcoid patients with normal pulmonary function. Sarcoidosis Vasc Diffuse Lung Dis. 19:2002;148-153
161. Mascolo M., Truwitt J. Role of exercise evaluation in restrictive lung disease: new insights between March 2001 and February 2003. Curr Opin Pulm Med. 9:2003;408-410
162. Costabel U. Sarcoidosis: clinical update. Eur Respir J. 18(Suppl 32):2001;56S-68S
163. Lynch J.P., Kazerooni E.A., Gay S.E. Pulmonary sarcoidosis. Clin Chest Med. 18(4):1997;755-785
164. Maña J., Salazar A., Pujol R., Manresa F. Are the pulmonary function tests and the markers of activity helpful to establish the prognosis of sarcoidosis? Respiration (Herrlisheim). 63:1996;298-303
165. Sharma O., Colp C., Williams M. Jr. Course of pulmonary sarcoidosis with and without corticosteroid therapy as determined by pulmonary function studies. Am J Med. 41:1966;541-551
166. Lieberman J., Schleissner L., Nosal A., Sastre A., Mishkin F. Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67Gallium scans, chest roentenograms, and pulmonary function. Chest. 84(5):1983;522-528
167. Finkel R., Teirstein A., Levine R., Brown L., Miller A. Pulmonary function tests, serum angiotensin-converting enzyme levels, and clinical findings as prognostic indicators in sarcoidosis. Ann N Y Acad Sci. 465:1986;665-671
168. Keogh B., Hunninghake G., Line B., Crystal R. The alveolitis of pulmonary sarcoidosis. Evaluation of natural history and alveolitis-dependent changes in lung function. Am Rev Respir Dis. 128:1983;256-265
169. Colp C. Sarcoidosis: course and treatment. Med Clin North Am. 61:1977;1267-1278
170. Shorr A., Davies D., Nathan S. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest. 124:2003;922-928
171. Drent M., Jacobs J., De Vries J., Lamers R., Liern I., Wouters E. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J. 13:1999;1338-1344
172. Baughman R., Winget D., Bowen E., Lower E. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 14:1997;154-158
173. Delobbe A., Durieu J., Duhamel A., Wallaert B. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Societe de Pathologie Thoracique du Nord. Eur Respir J. 9(10):1996;2002-2006
174. Basset F., Corrin B., Spencer H., Lacronique J., Roth C., Soler P., et al. Pulmonary histiocytosis X. Am Rev Respir Dis. 118(5):1978;811-820
175. Schonfeld N., Frank W., Wenig S., Uhrmeister P., Allica E., Preussler H., et al. Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration (Herrlisheim). 60(1):1993;38-44
176. Vassallo R., Ryu J., Schroeder D., Decker P., Limper A. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. 346:2002;484-490
177. Society A.T. Standardization of spirometry. Am Rev Respir Dis. 136:1987;1285-1298
178. Society A.T. Single-breath carbon monoxide diffusing capacity (transfer factor)-recommendations for a standard technique. 1995 Update. Am Rev Respir Crit Care Med. 152:1993;2185-2198
179. Kangalee K., Abbout R. Interlaboratory and intralaboratory variability in pulmonary function testing. A 13-year study using a normal biologic control. Chest. 101:1992;88-92
180. Crapo R. Carbon monoxide diffusing capacity (transfer factor). Seminars in Respiratory Critical Care Medicine. 19(4):1998;335-347
181. Douglas W., Ryu J., Swensen S., Offord K., Shroeder D., Caron G., et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Am J Respir Crit Care Med. 158:1998;220-225
182. Raghu G., Depaso W., Cain K., Hammar S., Wetzel C., Dreis D., et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis. 144:1991;291-296
183. Stack B., Choo-Kang Y., Heard B. The prognosis of cryptogenic fibrosing alveolitis. Thorax. 27:1972;535-542
184. Turner-Warwick M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid therapy and its effect on survival. Thorax. 35:1980;593-599
185. Flaherty K., Mumford J., Murray S., Kazerooni E., Gross B., Colby T., et
186. Collard H., King T., Bartelson B., Vourlekis J., Schwarz M., Brown K. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 168(5):2003;538-542
187. Raghu G., Mageto Y., Lockhart D., Schmidt R., Wood D., Godwin J. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest. 116:1999;1168-1174
188. Marciniuk D., Watts R., Gallagher C. Reproducibility of incremental maximal cycle ergometer testing in patients with restrictive lung disease. Thorax. 48:1993;894-898
189. Agusti A., Xaubet A., Agusti A., Roca J., Ramirez J., Rodriguez-Roisin R. Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up. Eur Respir J. 7(4):1994;643-650
190. van Oortegem K., Wallaert B., Marquette C., Ramon P., Perez T., Lafitte J., et al. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur Resir J. 7:1994;1950-1957
191. Flaherty K., Toews G., Lynch J. III, Kazerooni E., Gross B., Strawderman R., et al. Steroids in idiopathic pulmonary fibrosis: Prospective assessment of adverse reactions, response to therapy, and survival. Am J Med. 110:2001;278-282
192. Schneider P.D., Wise R.A., Hochberg M.C., Wigley F.M. Serial pulmonary function in systemic sclerosis. Am J Med. 73(3):1982;385-394
193. Colp C., Riker J., Williams M. Jr. Serial changes in scleroderma and idiopathic interstitial lung disease. Arch Intern Med. 132:1973;506-515
194. Witt C., Borges A., John M., Fietze I., Baumann G., Krause A. Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis. 58:1999;635-640
195. Abramson M., Barnett A., Littlejohn G., Smith M., Hall S. Lung function abnormalities and decline in spirometry in scleroderma: an overrated danger? Postgrad Med J. 67:1991;632-637
196. Bagg L.R., Hughes D.T. Serial pulmonary function tests in progressive systemic sclerosis. Thorax. 34(2):1979;224-228
197. Greenwald G., Tashkin D., Gong H., Simmons M., Duann S., Furst D., et al. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. Am J Med. 83:1987;83-92
198. Jacobsen S., Halberg P., Ullman S., Hoier-Madsen M., Petersen J., Mortensen J., et al. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheum. 16(4):1997;384-390
199. White B., Moore W., Wigley F., Xiao H., Wise R. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 132(12):2000;947-954
200. Peters-Golden M., Wise R., Schneider P.D., Hochberg M.C., Stevens M., Wigley F.M. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine (Baltimore). 63(4):1984;221-231
201. Silver R., Miller K., Kinsella M., Smith E., Schabel S. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 88:1990;470-476
202. Wells A.U., Hansell D.M., Rubens M.B., Cullinan P., Haslam P.L., Black C.M., et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med. 150(2):1994;462-468
203. Akesson A., Scheja A., Lundin A., Wollheim F. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 37(5):1994;729-735
204. Paramothayan S., Jones P. Corticosteroid therapy in pulmonary sarcoidosis. A systematic review. JAMA. 287:2002;1301-1307
205. Johns C., MacGregor M., Zachary J., Ball W. Extended experience in the long-term corticosteroid treatment of pulmonary sarcoidosis. Ann N Y Acad Sci. 278:1976;722-731
206. Emirgil C., Sobol B., Williams M. Jr. Long-term study of pulmonary sarcoidosis: the effect of steroid therapy as evaluated by pulmonary function studies. J Chron Dis. 22:1969;69-86
207. Odlum C., FitzGerald M.X. Evidence that steroids alter the natural history of previously untreated progressive pulmonary sarcoidosis. Sarcoidosis. 3:1986;40-46
208. Pietinalho A., Tukiainen P., Haahtela T., Persson T., Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 121:2002;24-31
209. Alhamad E.H., Lynch J.P. III, Martinez F.J. Pulmonary function tests in interstitial lung disease: what role do they have? Clin Chest Med. 22(4):2001;715-750. ix
210. Lawrence E., Teague R., Gottlieb M., Jhingran S., Lieberman J. Serial changes in markers of disease activity with corticosteroid treatment in sarcoidosis. Am J Med. 74:1983;747-756
211. Colp C., Park S., Williams M. Jr. Pulmonary function follow-up to 120 patients with sarcoidosis. Ann N Y Acad Sci. 278:1976;301-307
212. Zaki M., Lyons H., Leilop L., Huang C. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med. 87(9):1987;496-499
213. Goldstein D., Williams M. Rate of improvement of pulmonary function in sarcoidosis during treatment with corticosteroids. Thorax. 41:1986;473-474
214. Miller A., Brown L.K., Teirstein A.S. Stenosis of main bronchi mimicking fixed upper airway obstruction in sarcoidosis. Chest. 88(2):1985;244-248
215. Olsson T., Bjornstad-Pettersen H., Stjernberg N. Bronchostenosis due to sarcoidosis: a cause of atelectasis and airway obstruction simulating pulmonary neoplasm and chronic obstructive pulmonary disease. Chest. 75:1979;663-666
216. Sadoun D., Tandjoui H., Hirshi S., et al. Stenoses bronchiques proximales au cours de sarcoidosis mediastino-pulmonaires sans signe radiographique de fibrose: etude de 10 cas [abstract]. Rev Mal Respir. 12(Suppl 2):1995;A85
217. Lewis M., Horak D. Airway function in sarcoidosis. Chest. 92:1987;582-584
218. Coates R., Neville E. The development of airways obstruction in sarcoidosis among smokers and non-smokers. Sarcoidosis. 10:1993;115-117